E
enGene Therapeutics Inc. (ENGN)
NCM – Real vaqt narxi. Valyuta: USD
1.44
-0.05 (-3.36%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.44
+0.00 (0.01%)
Bozor oldidan: May 13, 2026, 7:26 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.44
-0.05 (-3.36%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.44
+0.00 (0.01%)
Bozor oldidan: May 13, 2026, 7:26 AM EDT
enGene Therapeutics Inc., oʻzining shoʻba korxonasi enGene, Inc. orqali Kanadada klinik bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. Kompaniya siydik pufagi saratonidan aziyat chekayotgan bemorlarga yordam berish uchun genetik dori vositalarini ishlab chiqadi. Uning asosiy mahsulot nomzodi – detalimogene voraplasmid, mushak invaziv boʻlmagan siydik pufagi saratonini (NMIBC) davolash uchun monoterapiya. Uning quvurida LEGEND mavjud boʻlib, u 2-bosqichda. Kompaniya avval enGene Holdings Inc. nomi bilan tanilgan va 2026-yil aprel oyida enGene Therapeutics Inc. nomiga oʻzgargan. enGene Therapeutics Inc. Monreal, Kanadada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alexander Nichols Ph.D. | Chief Strategy & Operations Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Hussein Sweiti M.D., M.Sc. | Chief Medical Officer and Head of Research & Development |
| Mr. David Ryan Daws | CFO & Head of Business Development |
| Mr. Lee G. Giguere | Chief Legal Officer & Corporate Secretary |
| Mr. Matthew Boyd | Chief Regulatory Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | ARS | ef20072042_ars.pdf |
| 2026-05-07 | 8-K | d335486d8k.htm |
| 2026-04-09 | 8-K | engn-20260407.htm |
| 2026-03-09 | S-8 | engn-20260309.htm |
| 2026-02-26 | CORRESP | filename1.htm |
| 2026-02-19 | S-3 | engn-20260219.htm |
| 2026-02-19 | 10-K/A | engn-20251031.htm |
| 2026-01-21 | 8-K | engn-20260120.htm |
| 2025-12-22 | 8-K | engn-20251222.htm |
| 2025-12-22 | 10-K | engn-20251031.htm |
| Mr. Ronald H. W. Cooper | President, CEO & Director |
| Ms. Jill Buck | Chief Development Officer |
| Ms. Joan Connolly | Chief Technology Officer |
| Ms. Tara Place M.B.A. | Senior VP of Human Resources |